Silo Pharma Inc.

Englewood Cliffs NJ, Dec. 02, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the issuance of a patent relating to its University Maryland Baltimore licensed homing peptide.  The novel homing peptide can be used for enhanced targeting of th... Read More...

Englewood Cliffs NJ, Aug. 25, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflamma... Read More...

Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin Englewood Cliffs NJ, July 27, 2021 -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announcedthat the United States Patent Office has issued a notic... Read More...

Englewood Cliffs NJ, July 12, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with the University of Maryland, Baltimore.  The main objective of our study is to evaluate the pharmacokinetics of dexamethasone delivered to arthri... Read More...

Englewood Cliffs, NJ, May 25, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has submitted its initial application to list on the NASDAQ Capital Market (“NASDAQ”).The Company previously announced its board approval to... Read More...

Englewood Cliffs, NJ, June 08, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA will leverage four ... Read More...

Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous SystemEnglewood Cliffs, NJ, Jan. 13, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PT... Read More...

Englewood Cliffs, NJ, Jan. 11, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million.  The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a li... Read More...

Englewood Cliffs, NJ, Jan. 06, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent ... Read More...